Abstract
Pulmonary embolism (PE) is a common and potentially life threatening disease if left untreated. This is due to a natural tendency towards early recurrence of pulmonary emboli which may lead to right ventricular failure. Thus, anticoagulant treatment should be administered to all patients upon high or intermediate clinical probability of acute PE, while awaiting definitive confirmation by imaging procedures. With the exception of severe renal impairment, high bleeding risk, arterial hypotension, and extremes of body weight and age, unfractionated heparin has been replaced by low molecular-weight heparin or fondaparinux given subcutaneously at weight-adjusted doses. In hemodynamically unstable patients with confirmed (high-risk) PE, thrombolysis should be administered without delay; if thrombolysis is absolutely contraindicated or has failed, surgical embolectomy or catheter-based thrombus removal is a valuable alternative. In normotensive (non-high-risk) patients, low-molecular-weight heparin or fondaparinux is adequate treatment in most cases, and thrombolysis is generally not recommended as a first-line therapeutic option. An ongoing randomized trial will determine whether normotensive patients with evidence of right ventricular dysfunction plus myocardial injury may benefit from early thrombolysis. Finally, selected normotensive patients without serious comorbidity or signs of heart failure (low-risk PE) may be candidates for out-of-hospital treatment. This strategy may be facilitated by the use of new oral anticoagulants in the future.
Keywords: Pulmonary embolism, venous thromboembolism, thrombolysis, heparin, anticoagulants.
Current Vascular Pharmacology
Title:Acute Phase Treatment of Pulmonary Embolism
Volume: 12 Issue: 3
Author(s): George Chalikias and Stavros Konstantinides
Affiliation:
Keywords: Pulmonary embolism, venous thromboembolism, thrombolysis, heparin, anticoagulants.
Abstract: Pulmonary embolism (PE) is a common and potentially life threatening disease if left untreated. This is due to a natural tendency towards early recurrence of pulmonary emboli which may lead to right ventricular failure. Thus, anticoagulant treatment should be administered to all patients upon high or intermediate clinical probability of acute PE, while awaiting definitive confirmation by imaging procedures. With the exception of severe renal impairment, high bleeding risk, arterial hypotension, and extremes of body weight and age, unfractionated heparin has been replaced by low molecular-weight heparin or fondaparinux given subcutaneously at weight-adjusted doses. In hemodynamically unstable patients with confirmed (high-risk) PE, thrombolysis should be administered without delay; if thrombolysis is absolutely contraindicated or has failed, surgical embolectomy or catheter-based thrombus removal is a valuable alternative. In normotensive (non-high-risk) patients, low-molecular-weight heparin or fondaparinux is adequate treatment in most cases, and thrombolysis is generally not recommended as a first-line therapeutic option. An ongoing randomized trial will determine whether normotensive patients with evidence of right ventricular dysfunction plus myocardial injury may benefit from early thrombolysis. Finally, selected normotensive patients without serious comorbidity or signs of heart failure (low-risk PE) may be candidates for out-of-hospital treatment. This strategy may be facilitated by the use of new oral anticoagulants in the future.
Export Options
About this article
Cite this article as:
Chalikias George and Konstantinides Stavros, Acute Phase Treatment of Pulmonary Embolism, Current Vascular Pharmacology 2014; 12 (3) . https://dx.doi.org/10.2174/157016111203140518154535
DOI https://dx.doi.org/10.2174/157016111203140518154535 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Membrane and Soluble Forms of Endoglin in Preeclampsia
Current Molecular Medicine Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Trypanosomatid Parasites Causing Neglected Diseases
Current Medicinal Chemistry New Generation Calcium Channel Blockers in Hypertensive Treatment
Current Hypertension Reviews Cucurbitacins and the Immune System: Update in Research on Anti- inflammatory, Antioxidant, and Immunomodulatory Mechanisms
Current Medicinal Chemistry Pharmacological Management Options to Prevent and Reduce Ischemic Hemorrhagic Transformation
Current Drug Targets Critical Congenital Heart Disease in Neonates: A Review Article
Current Pediatric Reviews Developing New Anti-Arrhythmics: Clues from the Molecular Basis of Cardiac Ryanodine Receptor (RyR2) Ca2+-Release Channel Dysfunction
Current Pharmaceutical Design The Adenine Nucleotide Translocase 2, a Mitochondrial Target for Anticancer Biotherapy
Current Drug Targets A Palliative Care Approach to the Advanced Heart Failure Patient
Current Cardiology Reviews Allosteric Drugs and Seven Transmembrane Receptors
Current Topics in Medicinal Chemistry Medicolegal Aspects of Disclosure of Side Effects of Biologic Drugs in Rheumatology: A Pilot Study
New Emirates Medical Journal Current Updates on Therapeutic Advances in the Management of Cardiovascular Diseases
Current Pharmaceutical Design The Multimodal Treatment of Acromegaly: Current Status and Future Perspectives
Endocrine, Metabolic & Immune Disorders - Drug Targets Downregulation of Hepatic Carbonyl Reductase Type 1 in End-Stage Renal Disease
Drug Metabolism Letters Use of Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Relation to Cardiovascular Events. A Systematic Pharmacoepidemiological Review
Current Vascular Pharmacology Therapeutic Hypothermia in Brain Injuries and Related Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Hyperhomocysteinemia and Sudden Cardiac Death: Potential Arrhythmogenic Mechanisms
Current Vascular Pharmacology Pathological Reorganization of NMDA Receptors Subunits and Postsynaptic Protein PSD-95 Distribution in Alzheimer’s Disease
Current Alzheimer Research Myelodysplastic Syndromes: Review of Pathophysiology and Current Novel Treatment Approaches
Current Cancer Drug Targets